Physician profile
Nathaniel Pelsor
NPI 1588977987
$4,247.37
in general payments reported to CMS, 2019-2025
32 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $168 · 2021: $564 · 2022: $500 · 2023: $531 · 2024: $1,007 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $715.00 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Alcon Vision LLC | $645.06 | 2019-2025 | Clareon Panoptix Pro, Tryptyr, Total30 |
| Regeneron Healthcare Solutions, INC. | $450.47 | 2019-2025 | Eylea Hd, Eylea |
| Sun Pharmaceutical Industries INC. | $307.79 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $302.97 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $271.76 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $239.95 | 2021-2025 | Acthar |
| Coopervision INC. | $185.04 | 2023-2024 | Misight Contact Lens, Myday Contact Lens |
| Lkc Technologies, INC. | $117.34 | 2024 | |
| Ani Pharmaceuticals, INC. | $114.00 | 2023-2025 | Purified Cortrophin Gel, Yutiq |
| Amgen INC. | $89.72 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $89.00 | 2022-2024 | Tyrvaya |
| Glaukos Corporation | $87.53 | 2021-2025 | Istent Infinite, Idosetr |
| Abbvie INC. | $58.09 | 2024-2025 | |
| Allergan, INC. | $58.05 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $56.82 | 2024-2025 | Triesence, Iheezo |
| Astellas Pharma US INC | $56.60 | 2024 | Izervay |
| Genentech USA, INC. | $50.97 | 2024-2025 | Vabysmo |
| Eyepoint US, INC. | $49.66 | 2021-2023 | |
| Horizon Therapeutics Plc | $34.26 | 2023 | Tepezza |
| Biotissue Holdings INC. | $31.87 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $28.39 | 2019 | |
| Aerie Pharmaceuticals, INC. | $25.78 | 2021 | |
| Recordati_rare_diseases_inc. | $25.34 | 2023 | Cystadrops |
| Johnson & Johnson Surgical Vision, INC. | $24.92 | 2020 | |
| Dompe US, INC. | $23.05 | 2025 | Oxervate |
| Shire North American Group INC | $21.92 | 2019 | |
| Sandoz INC. | $20.79 | 2024 | Cimerli |
| Carl Zeiss Meditec USA, INC. | $20.69 | 2024 | Lumera 700 |
| Alimera Sciences, INC. | $20.55 | 2023 | Yutiq |
| Coherus Oncology, INC. | $14.39 | 2022 | |
| Quidel Corporation | $9.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Pelsor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.